New study tracks Real-World use of secukinumab for painful skin condition

NCT ID NCT07543419

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 4 times

Summary

This study follows 250 Italian adults with moderate to severe hidradenitis suppurativa (HS) who are starting secukinumab. Researchers will track how well the drug reduces skin abscesses and tunnels over time, as well as treatment patterns and healthcare costs. The goal is to understand how secukinumab works in everyday practice, not just in controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Ancona, AN, 60126, Italy
Novartis Investigative Site
RECRUITING

Brescia, BS, 25123, Italy
Novartis Investigative Site
RECRUITING

Florence, FI, 50122, Italy
Novartis Investigative Site
RECRUITING

Lecce, LE, 73100, Italy
Novartis Investigative Site
RECRUITING

Messina, ME, 98125, Italy
Novartis Investigative Site
RECRUITING

Rozzano, MI, 20089, Italy
Novartis Investigative Site
RECRUITING

San Donato Milanese, MI, 20097, Italy
Novartis Investigative Site
RECRUITING

Trento, TN, 38100, Italy

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA